[HTML][HTML] Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease

RK Barr, BW Barber, JR Tait, CB Landersdorfer… - European Journal of …, 2023 - Elsevier
Background Regular intramuscular (im) benzathine penicillin G (BPG) injections have been
the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s …

Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis …

J Kado, S Salman, TK Hla, S Enkel… - Antimicrobial Agents …, 2023 - Am Soc Microbiol
Since 1955, the recommended strategy for rheumatic heart disease (RHD) secondary
prophylaxis has been benzathine penicillin G [BPG; 1.2 MU (900 mg)] injections …

Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD)

OD Montagnat, GR Webster, JB Bulitta… - Drug Delivery and …, 2018 - Springer
The current prophylactic treatment to prevent rheumatic heart disease requires four-weekly
intramuscular injection of a suspension of the poorly soluble benzathine salt form of …

Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of …

SL Enkel, J Kado, TK Hla, S Salman, J Bennett… - PloS one, 2023 - journals.plos.org
Introduction Secondary prophylaxis to prevent rheumatic heart disease (RHD) progression,
in the form of four-weekly intramuscular benzathine benzylpenicillin G (BPG) injections, has …

Subcutaneous infusions of high-dose Benzathine penicillin G (SCIP) is safe, tolerable and potentially suitable for less frequent dosing for rheumatic heart disease …

J Kado, S Salman, T Hla, S Enkel, R Henderson… - Heart, Lung and …, 2022 - Elsevier
Methods The safety, tolerability, and pharmacokinetics of SubCutaneous Infusions of high-
dose BPG (SCIP) was assessed in 24 healthy adult volunteers assigned to receive either …

Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared …

JH Kado, S Salman, R Henderson… - Journal of …, 2020 - academic.oup.com
Background Benzathine penicillin G has been used as monthly deep intramuscular (IM)
injections since the 1950s for secondary prevention of acute rheumatic fever and rheumatic …

[HTML][HTML] Local anaesthetic to reduce injection pain in patients who are prescribed intramuscular benzathine penicillin G: a systematic review and meta-analysis

F Pelone, B Kwok, S Ahmed, Y Kilic, SA Ali… - …, 2024 - thelancet.com
Background Three to 4-weekly intramuscular injections of benzathine penicillin G (BPG) for
a prolonged period (eg, 10 years, until age 40 years, or lifelong) are recommended for …

Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever

R Wyber, BJ Boyd, S Colquhoun, BJ Currie… - Drug Delivery and …, 2016 - Springer
Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal
infection. Secondary prophylaxis with antibiotics is recommended for people after their initial …

The risk of intramuscular haematoma is low following injection of benzathine penicillin G in patients receiving concomitant anticoagulant therapy

E Fox, J Misko, M Rawlins, L Manning - Journal of Thrombosis and …, 2020 - Springer
The use of intramuscular injections is widely recommended to be avoided in patients who
are prescribed anticoagulant agents, both oral and parenteral due to concerns of …

[HTML][HTML] Intramuscular versus Enteral Penicillin Prophylaxis to Prevent Progression of Rheumatic Heart Disease: Study protocol for a non-inferiority randomized trial …

J Rwebembera, E Ndagire, N Carvalho, AR Webel… - American Heart …, 2024 - Elsevier
ABSTRACT Background Rheumatic Heart Disease (RHD) persists as a major
cardiovascular driver of mortality and morbidity among young people in low-and middle …